The use of anti-PD1/PD-L1 monotherapy in patients with high tumor PD-L1 expression (≥50%) increased progression-free survival (PFS) and overall survival (OS), as shown in EMPOWER-Lung 1 [14], KEYNOTE-024 [15] and Impower110 [16] trials, which established single-agent immunotherapy as the standard first-line therapy for metastatic NSCLC patients without targeted alterations and high tumor PDL1 expression (≥50%). This evidence concerns the gene CD274 and neoplasm.